Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Glioblastoma Diagnosis and Monitoring through Nucleosome Epigenetic Modifications Tracking

Wednesday, October 15, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The poster titled 'Glioblastoma Diagnosis and Monitoring through Nucleosome Epigenetic Modifications Tracking' was presented at ISOBM 2025. It highlights the use of nucleosome epigenetic modifications as a novel approach for diagnosing and monitoring glioblastoma. The research emphasizes the prognostic value of the Nu.Q® Cancer Test.
Price reaction · baseline $9.214 (2025-10-14 close) · hit pre-market · 1 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-4.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation at a notable conference (ISOBM 2025).
  • Focus on innovative diagnostic methods for glioblastoma.
  • Potential for improved monitoring through epigenetic modifications.

Full Press Release Details

Poster titled: Glioblastoma Diagnosis and Monitoring through Nucleosome Epigenetic Modifications Tracking
P. Van den Ackerveken, J. Decarpentrie, C. Hannart, N. Hardat, M. Riva, N. Donis, F. George, L. d’Hondt, J. Douxilfs, M. Herzog.
Presented at ISOBM 2025

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What was presented at ISOBM 2025?

A poster on glioblastoma diagnosis and monitoring through nucleosome tracking.

What is the focus of the research?

The research focuses on using nucleosome epigenetic modifications for glioblastoma.

What is the Nu.Q® Cancer Test?

The Nu.Q® Cancer Test is highlighted for its prognostic value in the research.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare glioblastoma nucleosome epigenetic modifications Nu.Q® Cancer Test ISOBM 2025
Last updated: Oct 15, 2025

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk